Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Neuer Top-Geologe an Bord - zündet jetzt die nächste Kursrakete?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CM1C | ISIN: US75629V1044 | Ticker-Symbol:
NASDAQ
04.06.25 | 22:00
4,910 US-Dollar
0,00 % 0,000
1-Jahres-Chart
RECURSION PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
RECURSION PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur RECURSION PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrWas Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)?16
15.05.Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock35
09.05.Why Recursion Pharmaceuticals Stock Plummeted 24% This Week26
06.05.Why Recursion Pharmaceuticals Stock Is Plummeting Today14
06.05.Recursion axes drug programmes to streamline pipeline9
RECURSION PHARMACEUTICALS Aktie jetzt für 0€ handeln
06.05.RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates11
06.05.Recursion stock target cut to $8 by BofA on pipeline shifts8
05.05.Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday22
05.05.Recursion Pharmaceuticals outlines focused R&D pipeline with multiple catalysts through 20267
05.05.AI specialist Recursion trims pipeline in latest shakeup20
05.05.Several months after Exscientia merger, AI biotech outfit Recursion reworks pipeline19
05.05.Recursion Deprioritizes 3 Clinical Programs Following Data-Driven Review, Stock Down8
05.05.Recursion Pharmaceuticals GAAP EPS of -$0.50 beats by $0.06, revenue of $14.75M misses by $3.33M11
05.05.RECURSION PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans3
05.05.Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update402Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing...
► Artikel lesen
05.05.RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report2
05.05.RECURSION PHARMACEUTICALS, INC. - 10-Q, Quarterly Report2
04.05.Recursion Pharmaceuticals, Inc.: Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden245In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff.Five of six patients (83%) experienced...
► Artikel lesen
02.05.Recursion Pharmaceuticals Q1 2025 Earnings Preview7
28.04.Recursion Pharmaceuticals: Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th8
Seite:  Weiter >>
87 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,7